Skip to content

White discharge

A Randamized clinical control trial of yonigata swetastrava W.s.r to vaginitis With Pathaashilajityadi yoga and panchvalkal cream

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/028925
Enrollment
120
Registered
2020-11-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere

Interventions

Intervention1: Pathaa shilajityadi Yoga Panchvalkal Taila Pichu: Pathaa shilajityadi Yoga orally with 6 grams of dosage twice a day after food with rice water and Panchvalkal Taila Pichu Vaginally as

Sponsors

Parul Institute of Ayurved
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Married willing and cooperative women 2) Age between 20 years to 55 years. 3) The patients having clinical signs and symptoms of Yonigata Swetastrava i.e. features of white discharge with itching/ any abnormal smell/ swelling/redness. 4) Detection of pathogen by wet vaginal smear examination including any features either one/two/three/all. 5) Abstinence from sexual intercourse during study period or husband willing to use condoms during study period. 6) Hb > 7 gms%

Exclusion criteria

Exclusion criteria: 1) Unmarried women 2) Age below 20 years and above 55 years 3) Pregnant women, patient with IUCD, Contraceptive pills 4) Patients suffering from Tuberculosis, HIV, VDRL, DM, TORCH infection, Cervical erosion, prolapse, polyp, unexplained vaginal bleeding, Genital malignancy and Congenital and any other organic pathologies of reproductive tract. 5) PID-lower abdominal pain, leucorrhoea, rebound abdominal tenderness, dyspareunia, tenderness of uterus or fornics, fever, leukocytosis (at least 3 criteria positive) 6) Use of antibiotics or local vaginal formulation within the previous month 7) Hemoglobin less than 7 gm%

Design outcomes

Primary

MeasureTime frame
Amount of leucorrhoea and Local Symptom scoring for â??swelling, itching,redness etc-Timepoint: 7 days of treatment

Secondary

MeasureTime frame
Amount of leucorrhoea and Local Symptom scoring for â??swelling, itching,redness etc-Timepoint: after 1 month of treatment

Countries

India

Contacts

Public ContactDivyakumari Solanki

Parul Institute of Ayurved

asokan.v260043@paruluniversity.ac.in6361740431

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026